Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone

Publisher： Karger

E-ISSN： 1663-2826|84|3|172-183

ISSN： 1663-2818

Source： Hormone Research in Paediatrics, Vol.84, Iss.3, 2015-07, pp. : 172-183

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

European Audit of Current Practice in Diagnosis and Treatment of Childhood Growth Hormone Deficiency

By  

Hormone Research in Paediatrics, Vol. 58, Iss. 5, 2002-10 ,pp. : 233-241

Karger

Access to resources Recommend Favorite

Growth Hormone Treatment and Quality of Life among Survivors of Childhood Cancer

By  

Hormone Research in Paediatrics, Vol. 63, Iss. 6, 2005-08 ,pp. : 300-304

Karger

Access to resources Recommend Favorite

Catch-Up Growth after Childhood-Onset Substitution in Primary Hypothyroidism: Is It a Guide towards Optimal Growth Hormone Treatment in Idiopathic Growth Hormone Deficiency?

By  

Hormone Research in Paediatrics, Vol. 50, Iss. 5, 1999-01 ,pp. : 264-270

Karger

Access to resources Recommend Favorite

Seven Years of Safety and Efficacy of the Recombinant Human Growth Hormone Omnitrope® in the Treatment of Growth Hormone Deficient Children: Results of a Phase III Study

By  

Hormone Research in Paediatrics, Vol. 72, Iss. 6, 2009-10 ,pp. : 359-369

Karger

Access to resources Recommend Favorite

Growth Hormone Treatment: Cancer Risk

By  

Hormone Research in Paediatrics, Vol. 62, Iss. 3, 2004-11 ,pp. : 30-34

Karger

Access to resources Recommend Favorite